Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation

(2014) J Colquitt et al.   HEALTH TECHNOLOGY ASSESSMENT

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

(2010) Jakub Adamski et al.   BMC HEALTH SERVICES RESEARCH

Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers

(2010) Josh J. Carlson et al.   HEALTH POLICY

Canʼt Get No Satisfaction? Will Pay for Performance Help?

(2010) Adrian Towse et al.   PHARMACOECONOMICS

Access with Evidence Development Schemes

(2010) Christopher J. McCabe et al.   PHARMACOECONOMICS

Pharmaceutical Risk-Sharing Agreements

(2009) Joseph P Cook et al.   PHARMACOECONOMICS

The Impact of Two Pharmaceutical Risk-Sharing Agreements on Pricing, Promotion, and Net Health Benefits

(2009) Gregory S. Zaric et al.   VALUE IN HEALTH